Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Johnson, A. P.
Right arrow Articles by Livermore, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, A. P.
Right arrow Articles by Livermore, D. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 47, 411-415
© 2001 The British Society for Antimicrobial Chemotherapy

Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales

A. P. Johnsona,*, M. Warnera, R. C. Georgeb and D. M. Livermorea

a Antibiotic Resistance Monitoring and Reference Laboratory and b Respiratory and Systemic Infection Laboratory, Central Public Health Laboratory, Colindale, London NW9 5HT, UK

The activity of moxifloxacin was assessed against 1269 isolates of Streptococcus pneumoniae, comprising 462 isolates referred from UK hospitals, primarily for confirmation of resistance to first line agents, and 807 isolates from an enhanced surveillance of invasive infections. Resistance rates to penicillin, erythromycin, tetracycline and chloramphenicol were 88.7% (32.6% intermediate and 56.1% fully resistant), 50, 48 and 22.7%, respectively, for the former, and 8.0 (4.5% intermediate and 3.5% fully resistant), 14.7, 9.0 and 0.6% for the latter. Ninety-four per cent of the referred isolates and 99% of the surveillance isolates were susceptible to moxifloxacin at <=1 mg/L. Moxifloxacin may therefore be a useful drug for the treatment of patients with pneumococcal infections due to antibiotic-resistant strains or those with severe invasive disease.

* Corresponding author. Tel: +44-20-8200-4400 Ext. 4237; Fax: +44-20-8358-3292; E-mail: ajohnson{at}phls.nhs.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
T. A. Davies, R. Goldschmidt, S. Pfleger, M. Loeloff, K. Bush, D. F. Sahm, and A. Evangelista
Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000)
J. Antimicrob. Chemother., August 1, 2003; 52(2): 168 - 175.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
P. M. Shah
Determination of MICs in the routine laboratory
J. Antimicrob. Chemother., December 1, 2001; 48(6): 931 - 931.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.